Biodesix Inc
NASDAQ:BDSX

Watchlist Manager
Biodesix Inc Logo
Biodesix Inc
NASDAQ:BDSX
Watchlist
Price: 1.28 USD 6.67% Market Closed
Market Cap: 186.2m USD
Have any thoughts about
Biodesix Inc?
Write Note

Biodesix Inc
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biodesix Inc
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Biodesix Inc
NASDAQ:BDSX
Cash Interest Paid
$4m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DaVita Inc
NYSE:DVA
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Cash Interest Paid
$204m
CAGR 3-Years
5%
CAGR 5-Years
0%
CAGR 10-Years
N/A
CVS Health Corp
NYSE:CVS
Cash Interest Paid
-$2.8B
CAGR 3-Years
-4%
CAGR 5-Years
6%
CAGR 10-Years
-16%
Cigna Corp
NYSE:CI
Cash Interest Paid
$1.3B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
5%
Laboratory Corporation of America Holdings
NYSE:LH
Cash Interest Paid
$220.2m
CAGR 3-Years
5%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
No Stocks Found

Biodesix Inc
Glance View

Market Cap
186.2m USD
Industry
Health Care

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.

BDSX Intrinsic Value
1.93 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Biodesix Inc's Cash Interest Paid?
Cash Interest Paid
4m USD

Based on the financial report for Dec 31, 2023, Biodesix Inc's Cash Interest Paid amounts to 4m USD.

What is Biodesix Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 3Y
29%

Over the last year, the Cash Interest Paid growth was 295%. The average annual Cash Interest Paid growth rates for Biodesix Inc have been 29% over the past three years .

Back to Top